



| |
|----------------------------------|
| Dr. Alan Palkowitz, Ph.D. |
|----------------------------------|

Dr. Alan Palkowitz is Vice President, Discovery Chemistry Research & Technologies, Lilly Research Laboratories, Eli Lilly & Company.

He received his B.S. degree in Chemistry from the University of California at Berkeley in 1985 where he graduated valedictorian of the College of Chemistry. He then moved to the Massachusetts Institute of Technology where he obtained his Ph.D. in Synthetic Organic Chemistry in 1989 with Prof. William R. Roush.

Later that year, Dr. Palkowitz joined Lilly Research Laboratories as a Senior Organic Chemist in Cardiovascular Research where he focused on efforts targeting hypertension and atherosclerosis. Following a promotion to Research Scientist in 1992, he joined Endocrine Research and contributed to projects directed at osteoporosis and metabolic diseases. During this period, Dr. Palkowitz contributed to the discovery of several drug candidates, one of which is currently in advanced clinical testing for the treatment of osteoporosis and prevention of breast cancer. With a re-structuring of Discovery Chemistry in 1996, Dr. Palkowitz joined the scientific management team and was promoted to Head, Discovery Chemistry Research. In 1999 he became Director with a primary focus on developing and managing the lead generation infrastructure and strategy for the organization as well as oversight of the early stage drug discovery portfolio. In 2003, Dr. Palkowitz became Executive Director, Discovery Chemistry Research and Technologies. In this capacity he had responsibility for discovery lead generation, medicinal chemistry, computational sciences and structural biology, compound library sciences, quantitative biology and analytical technologies. Additionally, Dr. Palkowitz led several geography based initiatives aimed at globalization of discovery research. In 2006,

Dr. Palkowitz was promoted to Vice President, Discovery Chemistry Research & Technologies. He currently has responsibility for Lilly Global Discovery Chemistry which includes research sites in Indianapolis, Spain, the United Kingdom, San Diego and China. His organization is accountable for the discovery of drug candidates targeting Oncology, Neuroscience, Cardiovascular and Metabolic Diseases. Dr. Palkowitz also serves on several executive oversight committees that set strategic direction for the company.

Dr. Palkowitz is a co-author on numerous peer reviewed publications and is an inventor on more than fifty U.S. patents.